Rapamycina para cicatrices

Published in Dermatology

Journal Scan / Research · October 12, 2019

Topical Delivery of mTOR Inhibitor Halts Scarring

Journal of Dermatological Science

TAKE-HOME MESSAGE

• In this study, 16 mice serving as a well-established in vivo scar model were treated with rapamycin 0.2% gel (n=8) or vehicle alone (n=8). The treatment group showed statistically significant improvement in scar area and scar length compared with vehicle controls. Greater amounts of collagen I were observed in the treatment group whereas collagen III was more predominant in controls.

• This study provides preclinical evidence that topical application of the mTOR inhibitor rapamycin may be effective in reducing scarring. There is a known small risk of delayed wound healing with mTOR inhibitors; therefore, these findings suggest that they should be used during the remodeling phase of wound healing (after wound closure).

– Caroline Crabtree, MD

Abstract

Scar management is considered a major medical need affecting patients with large wounds, extensive burns, and enhanced genetic susceptibility for scar formation. Scarring impacts the human's well-being interfering with aesthetics, skin functions, and physical restriction of the body movement [1]. Scarring is not limited to the integumentary system (e.g., skin), it also affects multiple organs like the respiratory and digestive (e.g., lungs and salivary glands) systems, among others. Moreover, surgical interventions can also lead to undesired scarring and fibrosis, especially in the skin [2]. The development of novel pharmacological strategies targeting fibrosis and scarring constitute an urgent need to improve the lives of affected individuals. The biology of the scar formation is unique as it develops later after wound closure and during tissue maturation phase. Such a long course of scar formation provides a unique window of opportunity for pharmacological intervention.

Journal of Dermatological Science

Topical Delivery of mTOR Inhibitor Halts Scarring

J. Dermatol. Sci 2019 Aug 01;95(2)76-79, LP Webber, B Yip, CHVD Nascimento Filho, HB Park, RM Castilho, CH Squarize 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.